Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.

Masayuki Shirasawa,Tatsuya Yoshida,Yukiko Shimoda,Daisuke Takayanagi,Kouya Shiraishi,Takashi Kubo,Sachiyo Mitani,Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Hitoshi Ichikawa,Takashi Kohno,Noboru Yamamoto,Shun-ichi Watanabe,Noriko Motoi,Yuichiro Ohe

Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.

2021

Masayuki Shirasawa
Tatsuya Yoshida
Yukiko Shimoda
Daisuke Takayanagi
Kouya Shiraishi
Takashi Kubo
Sachiyo Mitani
Yuji Matsumoto
Ken Masuda
Yuki Shinno
Yusuke Okuma
Yasushi Goto
Hidehito Horinouchi
Hitoshi Ichikawa
Takashi Kohno
Noboru Yamamoto
Shun-ichi Watanabe
Noriko Motoi
Yuichiro Ohe

9044Background: Programmed death ligand-1 (PD-L1) expression is not a completely reliable predictive marker of the efficacy of anti-programmed cell death protein-1 (PD-1)/anti-PD-L1 therapy in adva...

Keywords:

Medicine
Lung cancer
non small cell
Programmed cell death
Cancer research
Predictive marker
PD-L1
Immune system
programmed death
Blockade

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations